Stathmin-2 (STMN2) (STMN2)

Stathmin-2 (STMN2), also known as SCG10, is a microtubule-destabilizing protein essential for axonal growth, maintenance, and regeneration (QurAlis, MDPI). It is highly expressed in motor neurons and regulates microtubule dynamics by binding to tubulin heterodimers, a process critical for neural repair and stability (PatSnap, R&D Systems). In neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), STMN2 is a key downstream target of the RNA-binding protein TDP-43 (Mass General, NIH). When TDP-43 mislocalizes from the nucleus to the cytoplasm—a hallmark of approximately 97% of ALS cases—it fails to suppress a cryptic exon in STMN2 pre-mRNA, leading to premature polyadenylation and the production of a non-functional, truncated protein (ALS News Today, NIH). This depletion of functional Stathmin-2 results in axonal degeneration and impaired regenerative capacity (Fight Aging, Neurology Live). Therapeutic strategies are currently focused on restoring STMN2 levels to preserve axonal integrity. The lead candidate, QRL-201, is an antisense oligonucleotide (ASO) designed to block the cryptic splice site and restore normal STMN2 expression (QurAlis, BioSpace). Other "designer DNA" drugs are also in development to correct STMN2 splicing independently of TDP-43 function (ALS News Today, Mass General). Biomarkers such as truncated STMN2 mRNA and protein levels in cerebrospinal fluid (CSF) are being developed to monitor target engagement and disease progression (QurAlis, ALS Society of Canada). Safety concerns include the need to maintain a precise balance of microtubule dynamics, as both excessive and insufficient STMN2 levels can impair neuronal health (NIH, Neurology).

Other names

SCG10SCGN10Superior cervical ganglion-10 proteinNeuron-specific growth-associated proteinStathmin-like 2

Restoration of STMN2 expression by using antisense oligonucleotides to block cryptic splicing and premature polyadenylation caused by TDP-43 loss.